Repligen Corporation is a bioprocessing company focused on the development, production, and commercialization of innovative products used in the process of manufacturing biologic drugs. The Company's customers include life sciences companies, global biopharmaceutical companies, and contract manufacturers worldwide.

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Quarterly Report (Amendment) (Form 10-Q/A | Period ending 2024-06-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Repligen Corp (RGEN US)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Quarterly Report (Amendment) (Form 10-Q/A | Period ending 2024-06-30)

Quarterly Report (Amendment) (Form 10-Q/A | Period ending 2024-03-31)

Annual Report (Amendment) (Form 10-K/A | Period ending 2023-12-31)

Quarterly Report (Amendment) (Form 10-Q/A | Period ending 2023-09-30)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)